Nustendi (Ezetimibe, Bempedoic Acid)

Ezetimibe, the active ingredient in Nustendi, is a combination lipid‑lowering agent presented as a tablet for oral use. It lowers elevated cholesterol levels and is used in adults who need additional lipid management alongside diet and statin therapy. GNH USA supplies Nustendi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Nustendi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nustendi is a combination lipid‑lowering therapy that targets cholesterol metabolism pathways.

- Primary hypercholesterolemia: helps achieve further LDL‑cholesterol reduction when statins alone are insufficient. - Heterozygous familial hypercholesterolemia: provides additional LDL‑cholesterol lowering in patients already on maximally tolerated statin therapy. - Mixed dyslipidemia: contributes to lowering of total cholesterol and non‑HDL cholesterol in patients with combined lipid abnormalities.

Nustendi may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Headache: mild to moderate intensity. - Muscle pain (myalgia): occasional. - Upper respiratory tract infection symptoms: such as sore sore. - Diarrhea: mild and self‑limiting. - Elevated liver enzymes: transient increase in laboratory tests.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown, rare but potentially life‑threatening. - Acute hepatic    ");

Precautions: - Monitor liver function: baseline and periodic testing recommended. - Assess cardiovascular risk: evaluate overall risk profile before initiating therapy. - Review concomitant statin dose: adjust if high‑intensity statin therapy is used. - Avoid in severe hepatic impairment: contraindicated in patients with significant liver disease. - Pregnancy: consider  ");

Interactions: Major -